Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 78

1.

Oxidative stress contributes to vascular calcification in patients with chronic kidney disease.

Huang M, Zheng L, Xu H, Tang D, Lin L, Zhang J, Li C, Wang W, Yuan Q, Tao L, Ye Z.

J Mol Cell Cardiol. 2020 Jan;138:256-268. doi: 10.1016/j.yjmcc.2019.12.006. Epub 2019 Dec 19.

2.

Assessment of biochemical recurrence of prostate cancer (Review).

Lin X, Kapoor A, Gu Y, Chow MJ, Xu H, Major P, Tang D.

Int J Oncol. 2019 Dec;55(6):1194-1212. doi: 10.3892/ijo.2019.4893. Epub 2019 Oct 4.

3.

The Central Contributions of Breast Cancer Stem Cells in Developing Resistance to Endocrine Therapy in Estrogen Receptor (ER)-Positive Breast Cancer.

Rodriguez D, Ramkairsingh M, Lin X, Kapoor A, Major P, Tang D.

Cancers (Basel). 2019 Jul 22;11(7). pii: E1028. doi: 10.3390/cancers11071028. Review.

4.

FAM84B promotes prostate tumorigenesis through a network alteration.

Jiang Y, Lin X, Kapoor A, He L, Wei F, Gu Y, Mei W, Zhao K, Yang H, Tang D.

Ther Adv Med Oncol. 2019 May 13;11:1758835919846372. doi: 10.1177/1758835919846372. eCollection 2019.

5.

Downregulation of CYB5D2 is associated with breast cancer progression.

Ojo D, Rodriguez D, Wei F, Bane A, Tang D.

Sci Rep. 2019 Apr 29;9(1):6624. doi: 10.1038/s41598-019-43006-y.

6.

Circulating Peroxiredoxin-1 is a novel damage-associated molecular pattern and aggravates acute liver injury via promoting inflammation.

He Y, Li S, Tang D, Peng Y, Meng J, Peng S, Deng Z, Qiu S, Liao X, Chen H, Tu S, Tao L, Peng Z, Yang H.

Free Radic Biol Med. 2019 Jun;137:24-36. doi: 10.1016/j.freeradbiomed.2019.04.012. Epub 2019 Apr 13.

PMID:
30991142
7.

The Contributions of Prostate Cancer Stem Cells in Prostate Cancer Initiation and Metastasis.

Mei W, Lin X, Kapoor A, Gu Y, Zhao K, Tang D.

Cancers (Basel). 2019 Mar 27;11(4). pii: E434. doi: 10.3390/cancers11040434. Review.

8.

The TGFβ-ERK pathway contributes to Notch3 upregulation in the renal tubular epithelial cells of patients with obstructive nephropathy.

Huang M, Zhang J, Xu H, Ding T, Tang D, Yuan Q, Tao L, Ye Z.

Cell Signal. 2018 Nov;51:139-151. doi: 10.1016/j.cellsig.2018.08.002. Epub 2018 Aug 4.

PMID:
30081092
9.

Construction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence.

Jiang Y, Mei W, Gu Y, Lin X, He L, Zeng H, Wei F, Wan X, Yang H, Major P, Tang D.

Mol Oncol. 2018 Sep;12(9):1559-1578. doi: 10.1002/1878-0261.12359. Epub 2018 Aug 11.

10.

Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development.

Gu Y, Chow MJ, Kapoor A, Mei W, Jiang Y, Yan J, De Melo J, Seliman M, Yang H, Cutz JC, Bonert M, Major P, Tang D.

Transl Oncol. 2018 Aug;11(4):1012-1022. doi: 10.1016/j.tranon.2018.06.003. Epub 2018 Jun 30.

11.

Etoposide-induced DNA damage affects multiple cellular pathways in addition to DNA damage response.

Wei F, Hao P, Zhang X, Hu H, Jiang D, Yin A, Wen L, Zheng L, He JZ, Mei W, Zeng H, Tang D.

Oncotarget. 2018 Feb 16;9(35):24122-24139. doi: 10.18632/oncotarget.24517. eCollection 2018 May 8.

12.

Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.

Ojo D, Lin X, Wu Y, Cockburn J, Bane A, Tang D.

Cancer Lett. 2018 Jul 10;426:4-13. doi: 10.1016/j.canlet.2018.03.048. Epub 2018 Apr 4.

PMID:
29626519
13.

A role of SIPL1/SHARPIN in promoting resistance to hormone therapy in breast cancer.

Ojo D, Wu Y, Bane A, Tang D.

Biochim Biophys Acta Mol Basis Dis. 2018 Mar;1864(3):735-745. doi: 10.1016/j.bbadis.2017.12.018. Epub 2017 Dec 14.

14.

Next Generation Quality: Assessing the Physician in Clinical History Completeness and Diagnostic Interpretations Using Funnel Plots and Normalized Deviations Plots in 3,854 Prostate Biopsies.

Bonert M, El-Shinnawy I, Carvalho M, Williams P, Salama S, Tang D, Kapoor A.

J Pathol Inform. 2017 Nov 23;8:43. doi: 10.4103/jpi.jpi_50_17. eCollection 2017.

15.

BMI1 reduces ATR activation and signalling caused by hydroxyurea.

Lin X, Wei F, Whyte P, Tang D.

Oncotarget. 2017 Sep 20;8(52):89707-89721. doi: 10.18632/oncotarget.21111. eCollection 2017 Oct 27.

16.

Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression.

Lin X, Gu Y, Kapoor A, Wei F, Aziz T, Ojo D, Jiang Y, Bonert M, Shayegan B, Yang H, Al-Nedawi K, Major P, Tang D.

Neoplasia. 2017 Nov;19(11):857-867. doi: 10.1016/j.neo.2017.06.006. Epub 2017 Sep 18.

17.

Signatures derived from increase in SHARPIN gene copy number are associated with poor prognosis in patients with breast cancer.

Ojo D, Seliman M, Tang D.

BBA Clin. 2017 Aug 24;8:56-65. doi: 10.1016/j.bbacli.2017.07.004. eCollection 2017 Dec.

18.

Microvesicles Contribute to the Bystander Effect of DNA Damage.

Lin X, Wei F, Major P, Al-Nedawi K, Al Saleh HA, Tang D.

Int J Mol Sci. 2017 Apr 7;18(4). pii: E788. doi: 10.3390/ijms18040788.

19.

Upregulation of FAM84B during prostate cancer progression.

Wong N, Gu Y, Kapoor A, Lin X, Ojo D, Wei F, Yan J, de Melo J, Major P, Wood G, Aziz T, Cutz JC, Bonert M, Patterson AJ, Tang D.

Oncotarget. 2017 Mar 21;8(12):19218-19235. doi: 10.18632/oncotarget.15168.

20.

Amplification of MUC1 in prostate cancer metastasis and CRPC development.

Wong N, Major P, Kapoor A, Wei F, Yan J, Aziz T, Zheng M, Jayasekera D, Cutz JC, Chow MJ, Tang D.

Oncotarget. 2016 Dec 13;7(50):83115-83133. doi: 10.18632/oncotarget.13073.

Supplemental Content

Loading ...
Support Center